C. G. Hartinger, S. Zorbas-seifried, M. A. Jakupec, B. Kynast, H. Zorbas et al., From bench to bedside?preclinical and early clinical development of the anticancer agent indazolium trans-[tetrachlorobis(1H-indazole)ruthenate(III)] (KP1019 or FFC14A), J. Inorg. Biochem, vol.100, pp.891-904, 2006.

M. J. Clarke, F. Zhu, and D. R. Frasca, Non-Platinum Chemotherapeutic Metallopharmaceuticals, Chem. Rev, vol.99, 1999.

M. J. Clarke, Ruthenium metallopharmaceuticals, Coord. Chem. Rev, vol.236, pp.209-233, 2003.

S. M. Meier-menches, C. Gerner, W. Berger, C. G. Hartinger, and B. K. Keppler, Structure?activity relationships for ruthenium and osmium anticancer agents ? towards clinical development, Chem. Soc. Rev, vol.47, pp.909-928, 2018.

A. Weiss, R. H. Berndsen, M. Dubois, C. Muller, R. Schibli et al., vivo anti-tumor activity of the organometallic ruthenium(II)-arene complex, vol.5, pp.4742-4748, 2014.

I. Kostova, Ruthenium complexes as anticancer agents, Curr. Med. Chem, vol.13, pp.1085-1107, 2006.

E. S. Antonarakis and A. Emadi, Ruthenium-based chemotherapeutics: are they ready for prime time?, Cancer Chemother. Pharmacol, vol.66, pp.1-9, 2010.

Z. Adhireksan, G. E. Davey, P. Campomanes, M. Groessl, C. M. Clavel et al., Ligand substitutions between ruthenium?cymene compounds can control protein versus DNA targeting and anticancer activity, Nat. Commun, vol.5, p.3462, 2014.

M. V. Babak, S. M. Meier, K. V. Huber, J. Reynisson, A. A. Legin et al., Target profiling of an antimetastatic RAPTA agent by chemical proteomics: relevance to the mode of action, Chem. Sci, vol.6, pp.2449-2456, 2015.

A. Dorcier, W. H. Ang, S. Bolanõ, L. Gonsalvi, L. Juillerat-jeannerat et al., In Vitro Evaluation of Rhodium and Osmium RAPTA Analogues: The Case for Organometallic Anticancer Drugs Not Based on Ruthenium, Organometallics, vol.25, pp.4090-4096, 2006.

A. A. Nazarov, C. G. Hartinger, and P. J. Dyson, Opening the lid on piano-stool complexes: An account of ruthenium(II)?arene complexes with medicinal applications, J. Organomet. Chem, vol.751, pp.251-260, 2014.

G. Suss-fink, Arene ruthenium complexes as anticancer agents

, Dalton Trans, pp.39-1673, 2010.

Y. K. Yan, M. Melchart, A. Habtemariam, and P. J. Sadler, Organometallic chemistry, biology and medicine: ruthenium arene anticancer complexes, Chem. Commun, pp.4764-4776, 2005.

C. Scolaro, A. Bergamo, L. Brescacin, R. Delfino, M. Cocchietto et al., In vitro and in vivo evaluation of ruthenium(II)-arene PTA complexes, J. Med. Chem, vol.48, pp.4161-4171, 2005.

R. E. Morris, R. E. Aird, P. Del-socorro-murdoch, H. Chen, J. Cummings et al., Inhibition of cancer cell growth by ruthenium(II) arene complexes, J. Med. Chem, vol.44, pp.3616-3621, 2001.

W. Kandioller, C. G. Hartinger, A. A. Nazarov, C. Bartel, M. Skocic et al., Maltol-Derived Ruthenium?Cymene Complexes with Tumor Inhibiting Properties: The Impact of Ligand?Metal Bond Stability on Anticancer Activity In Vitro, Chem. -Eur. J, vol.15, pp.12283-12291, 2009.

F. Aman, M. Hanif, W. A. Siddiqui, A. Ashraf, L. K. Filak et al., Anticancer Ruthenium(? 6 -p-cymene) Complexes of Nonsteroidal Anti-inflammatory Drug Derivatives, Organometallics, vol.33, pp.5546-5553, 2014.

E. Reisner, V. B. Arion, B. K. Keppler, and A. J. Pombeiro, Electron-transfer activated metal-based anticancer drugs, Inorg. Chim. Acta, vol.361, pp.1569-1583, 2008.

W. Kandioller, A. Kurzwernhart, M. Hanif, S. M. Meier, H. Henke et al., Pyrone derivatives and metals: From natural products to metal-based drugs, J. Organomet. Chem, vol.696, pp.999-1010, 2011.

W. Kandioller, E. Balsano, S. M. Meier, U. Jungwirth, S. Goschl et al., Organometallic anticancer complexes of lapachol: Metal centre-dependent formation of reactive oxygen species and correlation with cytotoxicity, Chem. Commun, vol.49, pp.3348-3350, 2013.

A. Gutie?rez, M. C. Gimeno, I. Marzo, and N. Metzler-nolte, Synthesis, Characterization, and Cytotoxic Activity of AuI N, S-Heterocyclic Carbenes Derived from Peptides Containing L-Thiazolylalanine, Eur. J. Inorg. Chem, pp.2512-2519, 2014.

R. H. Crabtree, NHC ligands versus cyclopentadienyls and phosphines as spectator ligands in organometallic catalysis, J. Organomet. Chem, vol.690, pp.5451-5457, 2005.

T. M. Trnka and R. H. Grubbs, The development of L 2 X 2 Ru CHR olefin metathesis catalysts: an organometallic success story, Acc. Chem. Res, vol.34, pp.18-29, 2001.

L. Oehninger, R. Rubbiani, and I. Ott, Heterocyclic carbene metal complexes in medicinal chemistry, Dalton Trans, vol.42, pp.3269-3284, 2013.

R. Rubbiani, E. Schuh, A. Meyer, J. Lemke, J. Wimberg et al., Ott, I. TrxR inhibition and antiproliferative activities of structurally diverse gold N-heterocyclic carbene complexes, MedChemComm, vol.4, pp.942-948, 2013.

W. Streciwilk, J. Cassidy, F. Hackenberg, H. Muller-bunz, F. Paradisi et al., Synthesis, cytotoxic and antibacterial studies of p-benzyl-substituted NHC?silver(I) acetate compounds derived from 4, 5-di-p-diisopropylphenyl-or 4, 5-di-p-chlorophenyl-1H-imidazole, J. Organomet. Chem, vol.749, pp.88-99, 2014.

C. Schmidt, B. Karge, R. Misgeld, A. Prokop, M. Bronstrup et al., Biscarbene gold(I) complexes: structure?activity-relationships regarding antibacterial effects, cytotoxicity, TrxR inhibition and cellular bioavailability, vol.8, pp.1681-1689, 2017.

L. Oehninger, H. Alborzinia, S. Ludewig, K. Baumann, S. Wolfl et al., From catalysts to bioactive organometallics: do Grubbs catalysts trigger biological effects, ChemMedChem, 2011.

L. Oehninger, M. Stefanopoulou, H. Alborzinia, J. Schur, S. Ludewig et al., Evaluation of arene ruthenium(II) Nheterocyclic carbene complexes as organometallics interacting with thiol and selenol containing biomolecules, Dalton Trans, vol.42, pp.1657-1666, 2013.

O. Karaca, S. M. Meier-menches, A. Casini, and F. E. Ku?n, On the binding modes of metal NHC complexes with DNA secondary structures: implications for therapy and imaging, Chem. Commun, vol.53, pp.8249-8260, 2017.

P. Mura, M. Camalli, A. Bindoli, F. Sorrentino, A. Casini et al., Activity of rat cytosolic thioredoxin reductase is strongly decreased by trans-[bis (2-amino-5-methylthiazole) tetrachlororuthenate (III)]: first report of relevant thioredoxin reductase inhibition for a ruthenium compound, J. Med. Chem, vol.50, pp.5871-5874, 2007.

S. Patil, J. Claffey, A. Deally, M. Hogan, B. Gleeson et al., Cytotoxicity and Antibacterial Studies of p-Methoxybenzyl-Substituted and Benzyl-Substituted N-Heterocyclic Carbene?Silver Complexes, Eur. J. Inorg. Chem, pp.1020-1031, 2010.

A. Neels, H. Stoeckli-evans, L. Plasseraud, E. G. Fidalgo, G. Suss-fink et al.,

, -para-cymene)iodoruthenium(II)] toluene solvate, Acta Crystallogr., Sect. C: Cryst. Struct. Commun, vol.55, issue.6, 1999.

J. M. Hayes, M. Viciano, E. Peris, G. Ujaque, and A. Lledo?, Mechanism of Formation of silver N-Heterocyclic Carbenes using Silver Oxide: a Theoretical Study, Organometallics, vol.26, pp.6170-6183, 2007.

M. Bennett, T. N. Huang, T. Matheson, A. Smith, S. Ittel et al., -Hexamethylbenzene) Ruthenium Complexes, Inorganic Syntheses

J. P. Fackler and . Jr, , vol.21, pp.74-78, 2007.

H. Kucukbay, B. Cetinkaya, S. Guesmi, and P. H. Dixneuf, New (carbene) ruthenium-arene complexes: preparation and uses in catalytic synthesis of furans, Organometallics, vol.15, pp.2434-2439, 1996.

J. R. Miecznikowski, N. A. Bernier, C. A. Van-akin, S. C. Bonitatibus, M. E. Morgan et al., Deactivation of a ruthenium(II) N-heterocyclic carbene p-cymene complex during transfer hydrogenation catalysis, Transition Met. Chem, vol.43, pp.21-29, 2018.

S. M. Meier, M. Hanif, Z. Adhireksan, V. Pichler, M. Novak et al., Novel metal(II) arene 2-pyridinecarbothioamides: A rationale to orally active organometallic anticancer agents, Chem. Sci, vol.4, pp.1837-1846, 2013.

B. Y. Tay, C. Wang, P. H. Phua, L. P. Stubbs, and H. V. Huynh, Selective hydrogenation of levulinic acid to [gamma]-valerolactone using in situ generated ruthenium nanoparticles derived from Ru-NHC complexes, Dalton Trans, vol.45, pp.3558-3563, 2016.

F. Wang, A. Habtemariam, E. P. Van-der-geer, R. Ferna?dez, M. Melchart et al., Controlling ligand substitution reactions of organometallic complexes: tuning cancer cell cytotoxicity, Proc. Natl. Acad. Sci. U. S. A, vol.102, pp.18269-18274, 2005.

Y. Fu, A. Habtemariam, A. M. Pizarro, S. H. Van-rijt, D. J. Healey et al., Organometallic Osmium Arene Complexes with Potent Cancer Cell Cytotoxicity, J. Med. Chem, pp.8192-8196, 2010.

H. Chen, J. A. Parkinson, R. E. Morris, and P. J. Sadler, Highly selective binding of organometallic ruthenium ethylenediamine complexes to nucleic acids: novel recognition mechanisms, J. Am. Chem. Soc, vol.125, pp.173-186, 2003.

C. Artner, H. U. Holtkamp, C. G. Hartinger, and S. M. Meier-menches, Characterizing activation mechanisms and binding preferences Inorganic Chemistry Article

, Inorg. Chem, vol.57, pp.14427-14434, 2018.

, of ruthenium metallo-prodrugs by a competitive binding assay, J. Inorg. Biochem, vol.177, pp.322-327, 2017.

C. Artner, H. U. Holtkamp, W. Kandioller, C. G. Hartinger, S. M. Meier-menches et al., DNA or protein? Capillary zone electrophoresis-mass spectrometry rapidly elucidates metallodrug binding selectivity, Chem. Commun, vol.53, pp.8002-8005, 2017.

M. P. Sullivan, M. K. Nieuwoudt, G. A. Bowmaker, N. Y. Lam, D. Truong et al., Unexpected arene ligand exchange results in the oxidation of an organoruthenium anticancer agent: the first X-ray structure of a protein-Ru(carbene) adduct, Chem. Commun, vol.54, pp.6120-6123, 2018.

Q. Cheng, T. Sandalova, Y. Lindqvist, and E. S. Arne?, Crystal structure and catalysis of the selenoprotein thioredoxin reductase 1, J. Biol. Chem, p.3998, 2009.

K. P. Bhabak, B. J. Bhuyan, and G. Mugesh, Bioinorganic and medicinal chemistry: aspects of gold (I)-protein complexes, Dalton Transactions, vol.40, 2011.

J. Zhang, Y. Liu, D. Shi, G. Hu, B. Zhang et al., Synthesis of naphthazarin derivatives and identification of novel thioredoxin reductase inhibitor as potential anticancer agent, Eur. J. Med. Chem, vol.140, pp.435-447, 2017.